Ribosomal Protein S27-Like in Colorectal Cancer: A Candidate for Predicting Prognoses

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Huang, Chi Jung ^a,b,c   Yang, Shung Haur ^d,e   Lee, Chia Long ^a,f   Cheng, Yu Che ^a   Tai, Szu Yun ^a   Chien, Chih Cheng ^a,b  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; RIBOSOMAL PROTEIN S37 LIKE; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL STRAIN LOVO; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DNA REPAIR; DNA SYNTHESIS INHIBITION; FECES ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

AGED; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DOWN-REGULATION; FECES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METALLOPROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN TRANSPORT; RIBOSOMAL PROTEINS; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS;

EID: 84879496806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067043     Document Type: Article

References (37)

1. Jass JR, (2006) Colorectal cancer: a multipathway disease. Crit Rev Oncog 12: 273-287.
2. Vogelstein B, Fearon ER, Hamilton SR, (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
3. Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, et al. (2010) Stage II and stage III colon cancer: treatment advances and future directions. Cancer J 16: 202-209.
4. Kosmider S, Lipton L, (2007) Adjuvant therapies for colorectal cancer. World J Gastroenterol 13: 3799-3805.
5. Chun P, Wainberg ZA, (2009) Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. Gastrointest Cancer Res 3: 191-196.
6. Iacopetta B, (2003) TP53 mutation in colorectal cancer. Hum Mutat 21: 271-276.
7. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, et al. (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717-7722.
8. Bolderson E, Richard DJ, Zhou BB, Khanna KK, (2009) Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 15: 6314-6320.
9. Chen F, Wang W, El-Deiry WS, (2010) Current strategies to target p53 in cancer. Biochem Pharmacol 80: 724-730.
10. Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan M, Oren M, (2008) Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell 32: 180-189.
11. Panić L, Tamarut S, Sticker-Jantscheff M, Barkić M, Solter D, et al. (2006) Ribosomal protein S6 gene haploinsufficiency is associated with activation of a p53-dependent checkpoint during gastrulation. Mol Cell Biol 26: 8880-8891.
12. Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, et al. (2013) mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers. PLoS One 8: e60709.
13. Figarola JL, Rahbar S, (2013) Small-molecule COH-SR4 inhibits adipocyte differentiation via AMPK activation. Int J Mol Med 31: 1166-1176.
14. Kapoor NR, Ahuja R, Shukla SK, Kumar V, (2013) The HBx protein of hepatitis B virus confers resistance against nucleolar stress and anti-cancer drug-induced p53 expression. FEBS Lett 587: 1287-1292.
15. Huang CJ, Chien CC, Yang SH, Chang CC, Sun HL, et al. (2008) Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. J Cell Mol Med 12: 1936-1943.
16. Tien LT, Chien CC, Yang SH, Lin CM, Wu YY, et al. (2010) p53-Dependent Expression of Ribosomal Protein S27-Like in Colorectal Cancer. Fu-Jen J Med 8: 11-17.
17. Thomas EA, Alvarez CE, Sutcliffe JG, (2000) Evolutionarily distinct classes of S27 ribosomal proteins with differential mRNA expression in rat hypothalamus. J Neurochem 74: 2259-2267.
18. Fernandez-Pol JA, (2011) Conservation of multifunctional ribosomal protein metallopanstimulin-1 (RPS27) through complex evolution demonstrates its key role in growth regulation in Archaea, eukaryotic cells, DNA repair, translation and viral replication. Cancer Genomics Proteomics 8: 105-126.
19. Li J, Tan J, Zhuang L, Banerjee B, Yang X, et al. (2007) Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res 67: 11317-11326.
20. Xiong X, Zhao Y, He H, Sun Y, (2011) Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene 30: 1798-1811.
21. Chien CC, Chen SH, Liu CC, Lee CL, Yang RN, et al. (2007) Correlation of K-ras codon 12 mutations in human feces and ages of patients with colorectal cancer (CRC). Transl Res 149: 96-102.
22. Zou J, Luo H, Zeng Q, Dong Z, Wu D, et al. (2011) Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. J Transl Med 9: 97.
23. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, et al. (2010) The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21: 2396-2402.
24. Yang SH, Lin JK, Lai CR, Chen CC, Li AF, et al. (2004) Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol 87: 167-173.
25. Katoh H, Yamashita K, Kokuba Y, Satoh T, Ozawa H, et al. (2008) Diminishing impact of preoperative carcinoembryonic antigen (CEA) in prognosis of Dukes' C colorectal cancer. Anticancer Res 28: 1933-1941.
26. Svobodova S, Topolcan O, Holubec LJ, Levy M, Pecen L, et al. (2011) Parameters of biological activity in colorectal cancer. Anticancer Res 31: 373-378.
27. Pan J, Zhong J, Gan LH, Chen SJ, Jin HC, et al. (2011) Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. Tumour Biol 32: 729-735.
28. Díaz-Perales A, Quesada V, Peinado JR, Ugalde AP, Alvarez J, et al. (2005) Identification and characterization of human archaemetzincin-1 and-2, two novel members of a family of metalloproteases widely distributed in Archaea. J Biol Chem 280: 30367-30375.
29. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006.
30. Herceg Z, Wang ZQ, (2001) Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 477: 97-110.
31. Tell G, Wilson DMr, (2010) Targeting DNA repair proteins for cancer treatment. Cell Mol Life Sci 67: 3569-3572.
32. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T, (2003) The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 105: 472-479.
33. Maser RS, Mirzoeva OK, Wells J, Olivares H, Williams BR, et al. (2001) Mre11 complex and DNA replication: linkage to E2F and sites of DNA synthesis. Mol Cell Biol 21: 6006-6016.
34. Chen D, Yu Z, Zhu Z, Lopez CD, (2008) E2F1 regulates the base excision repair gene XRCC1 and promotes DNA repair. J Biol Chem 283: 15381-15389.
35. Takahashi M, Koi M, Balaguer F, Boland CR, Goel A, (2011) MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem 286: 12157-12165.
36. Jackson SP, Bartek J, (2009) The DNA-damage response in human biology and disease. Nature 461: 1071-1078.
37. Miquel C, Jacob S, Grandjouan S, Aimé A, Viguier J, et al. (2007) Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26: 5919-5926.